5 results on '"Bataller, Alex"'
Search Results
2. Real-World Data on Chronic Myelomonocytic Leukemia : Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes
- Author
-
Castaño-Díez, Sandra, López-Guerra, Mónica, Bosch-Castañeda, Cristina, Bataller, Alex, Charry, Paola, Esteban, Daniel, Guijarro, Francesca, Jiménez-Vicente, Carlos, Castillo-Girón, Carlos, Cortes, Albert, Martínez-Roca, Alexandra, Triguero, Ana, Álamo, José Ramón, Bea, Sílvia, Costa, Dolors, Colomer, Dolors, Rozman, María, Esteve Reyner, Jordi, Díaz-Beyá, Marina, and Universitat Autònoma de Barcelona
- Subjects
chronic myelomonocytic leukemia ,CMML ,AML transformation ,clonal evolution ,prognosis ,treatment ,hypomethylating agents ,targeted therapy ,gene mutations ,survival ,Cancer Research ,Leukemia ,Oncology ,Leucèmia ,Molecular genetics ,Genètica molecular - Abstract
This research was supported by grants from resident award Contractes Clínic de Recerca Emili Letang-Josep Font 2021, granted by Hospital Clínic de Barcelona; and it was funded by Instituto de Salud Carlos III (ISCIII) through the project "FIS PI19/01476" and co-funded by the European Union. Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid leukemia (AML). In a single-center cohort of 219 CMML patients, we explored the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and clonal evolution into AML. The most commonly detected mutations were TET2, SRSF2, ASXL1, and RUNX1. Median OS was 34 months and varied according to age, cytogenetic risk, FAB, CPSS and CPSS-Mol categories, and number of gene mutations. Hypomethylating agents were administered to 37 patients, 18 of whom responded. Allogeneic stem cell transplantation (alloSCT) was performed in 22 patients. Two-year OS after alloSCT was 60.6%. Six patients received targeted therapy with IDH or FLT3 inhibitors, three of whom attained a long-lasting response. AML transformation occurred in 53 patients and the analysis of paired samples showed changes in gene mutation status. Our real-world data emphasize that the outcome of CMML patients is still unsatisfactory and alloSCT remains the only potentially curative treatment. However, targeted therapies show promise in patients with specific gene mutations. Complete molecular characterization can help to improve risk stratification, understand transformation, and personalize therapy
- Published
- 2022
3. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
- Author
-
Oñate, Guadalupe, Bataller, Alex, Garrido, Ana, Hoyos Colell, Montserrat, Arnan, Montserrat, Vives Polo, Susana, Coll, Rosa, Tormo, Mar, Sampol, Antònia, Escoda, Lourdes, Salamero, Olga, Garcia, Antoni, Bargay, Joan, Aljarilla, Alba, Nomdedeu, Josep, Esteve Reyner, Jordi, Sierra, Jorge, Pratcorona, Marta, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Oñate G, Garrido A, Hoyos M] Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. [Bataller A] Hospital Clínic, Barcelona, Spain. [Arnan M] Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, Barcelona, Spain. [Vives S] ICO, Hospital Germans Trias i Pujol, Jose Carreras Leukemia Research Institute, Badalona, Spain. [Salamero O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,NPM1 ,Neoplasm, Residual ,Leucèmia mieloide ,Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES] ,Leucèmia mieloide aguda - Prognosi ,Intensive chemotherapy ,medicine.disease_cause ,Allelic ratio ,Gastroenterology ,DNA Methyltransferase 3A ,neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES] ,fluids and secretions ,hemic and lymphatic diseases ,Internal medicine ,Other subheadings::Other subheadings::/genetics [Other subheadings] ,Humans ,Medicine ,Mutational status ,In patient ,Diagnosis::Prognosis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS] ,Mutation ,Otros calificadores::Otros calificadores::/genética [Otros calificadores] ,business.industry ,Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES] ,Nuclear Proteins ,hemic and immune systems ,Hematology ,Prognosis ,Acute Myeloid Leukemia with Mutated NPM1 ,Enzymes ,body regions ,Leukemia, Myeloid, Acute ,Anomalies cromosòmiques ,Myeloid leukemia ,Leucèmia mieloide aguda - Aspectes genètics ,embryonic structures ,High ratio ,Enzims ,business ,Nucleophosmin - Abstract
Prognostic impact; Mutation; Acute myeloid leukemia Impacte pronòstic; Mutació; Leucèmia mieloide aguda Impacto pronóstico; Mutación; Leucemia mieloide aguda The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD−; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention. This work was supported in part by the Biomedical Research Institute (IIB Sant-Pau) and the José Carreras Leukemia Research Institute as well as grants from the Catalan Government (PERIS SLT002/16/0043 and AGAUR 2017 SGR 139) and the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain (PI17/01246, PI20/01621 and CM20/00061).
- Published
- 2021
4. Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma.
- Author
-
Mozas, Pablo, Rivero, Andrea, Rivas‐Delgado, Alfredo, Fabregat, Aleix, Piñeyroa, Juan A., Correa, Juan G., Nadeu, Ferran, Oliver, Aina, Bataller, Alex, Giné, Eva, Delgado, Julio, Villamor, Neus, Cibeira, Maria T., Fernández de Larrea, Carlos, Rosiñol, Laura, Campo, Elías, Aróstegui, Juan I., Bladé, Joan, Magnano, Laura, and López‐Guillermo, Armando
- Subjects
BLOOD proteins ,LYMPHOMAS ,MONOCLONAL gammopathies ,PROGRESSION-free survival ,DIAGNOSIS - Abstract
Summary: The presence of a serum monoclonal component has been associated with poor outcomes in some lymphomas. However, data in follicular lymphoma (FL) are scarce. We studied 311 FL patients diagnosed at a single institution, for whom information on serum immunofixation electrophoresis (sIFE) at diagnosis was available. Baseline characteristics and outcomes were compared between patients with a positive (+sIFE) and a negative sIFE (−sIFE). sIFE was positive in 82 patients (26%). Baseline features were comparable between both groups, except for an older age and higher proportion of elevated β2‐microglobulin levels in the +sIFE group. With a median follow‐up of 4.6 years, a +sIFE was associated with a higher risk of early relapse (POD24, 27% vs. 15%, P = 0·02), shorter progression‐free survival (PFS; 42% vs. 52% at 5 years, P = 0·008), and shorter overall survival (OS; 59% vs. 77% at 10 years, P = 0·046). In patients >60 years, a +sIFE was an independent predictor of OS [hazard ratio (HR) = 2·4, 95% confidence interval (CI): 1·2–5·0; P = 0·02]. Approximately one quarter of patients with FL has a +sIFE at diagnosis, which is a predictor of poor outcome. These findings encourage further investigation of its relationship with B‐cell biology and the tumour microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma.
- Author
-
Mozas, Pablo, Rivero, Andrea, Rivas-Delgado, Alfredo, Nadeu, Ferran, Clot, Guillem, Correa, Juan Gonzalo, Castillo, Carlos, Bataller, Alex, Baumann, Tycho, Giné, Eva, Delgado, Julio, Villamor, Neus, Campo, Elías, Pérez-Galán, Patricia, Magnano, Laura, and López-Guillermo, Armando
- Subjects
LYMPHOMAS ,PROGRESSION-free survival ,DIAGNOSIS ,PROGNOSIS ,FOLLICULAR lymphoma - Abstract
The lymphocyte-to-monocyte ratio (LMR) is a prognostic factor in different neoplasms, but its potential importance in follicular lymphoma (FL) is not well defined. We studied 384 FL patients for which the LMR was available at diagnosis. Baseline features and outcomes were compared between patients with an LMR ≤/>2.5. The 76 patients (20%) who had an LMR ≤2.5 were older and had a higher tumor burden. A low LMR was predictive of a lower 10-y progression-free survival (32 vs. 55%, p =.001) and overall survival (35 vs. 78%, p <.0001; HR = 2.3, p =.003 in a 6-element multivariable model). A low LMR was also an independent risk factor for histological transformation (11 vs. 6% at 10 years, p =.01). Likewise, patients with a low LMR had a higher rate of second malignancies. The potential utility of this widely available parameter and its contribution to well-established prognostic scores need to be explored in independent, prospective series. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.